The 9th Amsterdam Immunogenicity & Tolerance Seminar will take place on Friday, November 10th from 10:00AM – 6:00PM. All events (including a cocktail networking hour!) will be located at the Hilton Apollolaan in Amsterdam.
About the Amsterdam Immunogenicity & Tolerance Seminar:
Now in its 9th year, the Amsterdam Immunogenicity & Tolerance Seminar has become a much-anticipated forum for sharing research and ideas in the fields of immunogenicity and tolerance. Academic and industry research has progressed significantly in the past several years, and many advances have been made in the areas of gene therapy, mRNA, CAR-T, and other novel platforms. In addition, traditional protein therapeutics research (still somewhat new as well), has expanded complexity to include Bispecific and Multispecifc antibodies, fusion proteins, and peptide therapeutics. All these exciting developments have generated many questions and added complexity for immunologists, drug developers and medical practitioners working to deliver safe and effective therapies.
Please note, this is an in-person event with no option for virtual attendance.
2023 speakers are to include:
CEO / CSO
EpiVax Inc.
Principle Investigator in the Division of Infection and Immunity in Cardiff University
Honorary Consultant Physician in the University Hospital of Wales
Outflanking Viruses and Cancer with CD4+ T Cells – Translating Experimental Findings to Human Studies
Chief Scientific Officer and Chief Technology Officer
EpiVax Therapeutics
AI-Identification of Self-Like Neoantigens for Developing Enhanced Precision Immunotherapies
Sr. Lecturer in Immunology
University of Surrey
An in vitro Immune Organoid System for Studying Vaccine-Induced Activation of T Cell and Antibody Responses in Humans
Professor of Pediatrics, Head of Pediatric Intensive Care and Pediatric Infectious Diseases
University Medical Center of Johannes Gutenberg University
Modification of Regulatory T Cell Epitopes Promotes Effector T Cell Responses to a Tumor Antigen
Director, Translational Immunology
University of Southampton
Targeting FcRn for the Therapy of Autoimmunity
Sébastien Lacroix-Desmazes, PhD
Director of Research, Immunopathology and Therapeutic Immuno-intervention
Cordeliers Research Center
Transplacental Delivery of Therapeutic Proteins Engineered by IgG
Professor of Translational Immunology, Faculty of Veterinary Medicine
Utrecht University
Approach to Therapeutic Tolerance in Rheumatoid Arthritis
Professor & Laboratory Head, Laboratory of Reproductive Immunology
Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences
Check out past year’s AIT Seminars:
2022 Amsterdam Immunogenicity & Tolerance Seminar
2021 Amsterdam Immunogenicity & Tolerance Seminar
2019 Amsterdam Immunogenicity & Tolerance Seminar
Register Now!
A special thanks to the AIT23 Organizing Committee:
Annie De Groot, MD (CEO/CSO, EpiVax Inc.), Brian Roberts, PhD (Scientific Director, Preclinical Immunology, EpiVax Inc.), Corine Kruiswijk (Director, Translational Research, Intravacc), Christiane Gerke, PhD (Head of Vaccine Programs & Vaccine Innovation Development, Institut Pasteur), Marcel Hoefnagel (Senior Scientist/Assessor, College ter Beoordeling van Geneesmiddelen), and Elly van Riet (Senior Scientist, TuBerculosis Vaccine Initiative)
Questions or suggestions? Contact EpiVax: info@epivax.com
COVID-19 Policy: The Westin Immunogenicity Seminar will follow all Japanese COVID-19 guidelines. There will be COVID-19 rapid tests available if you would like to test yourself prior to entering the Seminar. There will also be masks available at arrival.